TP53 and neoplasm: In clinical perspective, albeit we confirm that loss of TP53 function (as well as gain of PI3K function) do enhance the response to KU60019 radiosensitization12, we have shown by analysis of multiple patients, that even tumors with unfavorable properties (elevated TP53 and reduced PI3K wild type expressions) can be radiosensitized by KU60019, although less promptly than GIC-driven tumours bearing the “responder” profile, thus making reasonable the treatment of an elevated percentage of HGG patients with ATMi13.